| abstract |
A pharmaceutical composition comprising a pharmaceutical diluent and a compound of formula IVn nwherein R 21 = H, C 1 -C 20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, -CH 2 OR 25 , -C(O)R 25 , -CO(O)R 25 , -C(O)NR 25 R 26 , -CH 2 C(O)R 25 , or -CH 2 C(O)NHR 25 , where R 25 and R 26 are each independently H, C 1 -C 10 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, optionally containing one or more halogen atoms. R 22 -OH, -OR 27 , -OCH 2 C(O)R 27 , -OCH 2 C(O)NHR 27 , -OC(O)R 27 , -OC(O)OR 27 , -OC(O)NHNH-R 5 , or -OC(O)NR 27 R 28 , where R 27 and R 28 are each independently H, C 1 -C 20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, and where R 27 and R 28 can each optionally contain halogen atoms; R 23 and R 24 , the same or different from each other, are C 1 -C 20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl. Methods of using such formulations for the treatment of cancer, to effect weight loss, to treat microbially-based infections, to inhibit neuropeptide-Y and/or fatty acid synthase, and to stimulate CPT-1. |